CAS: 125-60-0; 4-(1-Methylpiperidin-1-Ium-1-yl)-2,2-Diphenylbutanamide,Bromide
该化合物是一种主要用作抗胆碱基剂的四硝基铵化合物,其特点是它能够抑制肌肉受体的乙酰胆碱化作用,从而产生诸如降低滑动肌肉收缩和分泌效应等效应;该化合物通常用于治疗胃肠紊乱,特别是缓解与肠胃肠综合症等条件有关的抽搐和不适;苯丙烯基溴是一种白到白的晶状粉,可溶于水和酒精,便于其施用各种药剂;其药理学特征包括行动较快的开始,使其对急性症状的缓解有效;然而,与许多抗胆碱化物一样,它可能会产生副作用,如干口,视力模糊和由于系统抗胆碱性效应而导致的尿保留;安全和功效特征有很好的记载,在开药时必须考虑与其他药物的反作用和潜在相互作用.
- 英文名称4-(1-Methylpiperidin-1-Ium-1-yl)-2,2-Diphenylbutanamide,Bromide
- 中文名称苯维溴铵
- IUPAC名称1-(4-amino-4-oxo-3,3-diphenylbutyl)-1-methylpiperidin-1-ium bromide
- 其它别名1-(3-Carbamoyl-3,3-diphenylpropyl)-1-methylpiperidiniumbromide (6CI,7CI); Piperidinium, 1-(3-carbamoyl-3,3-diphenylpropyl)-1-methyl-,bromide (8CI); Piperidinium, 1-(4-amino-4-oxo-3,3-diphenylbutyl)-1-methyl-,bromide (9CI); 2,2-Diphenyl-2-(2-piperidinoethyl)acetamide methylbromide; 2-(Diphenylpiperidinoethyl)acetamide methobromide; 2-(Diphenylpiperidinoethyl)acetamide methyl bromide; Baralgin-Amid; Baralgin-Amide; Bulgar amide; Fenpipramide methobromide; Fenpiverinium bromide; Resantin; a,a-Diphenyl-1-piperidinebutyramidemethobromide; a,a-Diphenyl-g-piperidylbutyramide methobromide
- CAS编号125-60-0
- MFCD编号:MFCD00865184
- EINECS号:204-744-9
- FDA UNII编号:36479UA8GL
- 分子式:C22H29BrN2O分子量:417.38
- 产品CID: 380572
- 产品分类有机原料 → 苯类化合物 → 苯取代衍生物
物理性质
MSDS等安全信息
欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
CAS号74-83-9 溴甲烷 | CAS号77-01-0 Fenpipramide合成工艺路线路线简述
📜溴甲烷,2,2-二苯基-4-哌啶-1-基丁酰胺 反应生成苯维溴铵
参考文献:Moffett; Aspergren,Journal Of The American Chemical Society,1957,Vol. 79,P. 4462,4464,4465
标题:Moffett; Aspergren,Journal Of The American Chemical Society,1957,Vol. 79,P. 4462,4464,4465
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2912110000-甲醛
2912120000-乙醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-7993390-B2
优先权日:2002-02-08
标 题:Implantable or insertable medical device resistant to microbial growth and biofilm formation
发明人：MILLER KATHLEEN M; BUCAY-COUTO WEENNA; LI JIANMIN
权利人:BOSTON SCIENT SCIMED INC
摘要:Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and/or a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Chaudhary A, Gupta RL. Double blind, randomised, parallel, prospective, comparative, clinical evaluation of a combination of antispasmodic analgesic Diclofenac + Pitofenone + Fenpiverinium (Manyana) vs Analgin + Pitofenone + Fenpiverinium (Baralgan) in biliary, ureteric and intestinal colic. J Indian Med Assoc. 1999 Feb;97(2):72-5. 97(9):398-400. 97(6):244-5.
102:85-92. doi: 10.1016/j.jpba.2014.09.002. Epub 2014 Sep 16.
合成参考文献
摘要:Journal of the American Chemical Society., 79(4451), 1957
摘要:Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie., 224(357), 1955 []
摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
📝 需求与反馈
尽可能描述清楚需求与问题信息
